Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How to decrease p27Kip1 levels during tumor development.

Andrew Koff1

  • 1Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA. a-koff@ski.mskcc.org

Cancer Cell
|February 14, 2006
PubMed
Summary

The tumor suppressor p27Kip1’s levels decrease in cancer through unknown posttranscriptional mechanisms. New mouse models reveal surprising insights into the pathways controlling p27Kip1 turnover during tumor development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal for immunotherapy of cancer·2026
Same author

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Cancer research communications·2025
Same author

Cell cycle dysregulation in cancer.

Pharmacological reviews·2025
Same author

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.

Cancer cell·2024
Same author

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.

Cancer cell·2024
Same author

The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.

Future oncology (London, England)·2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • p27Kip1 is a critical cyclin-dependent kinase inhibitor and tumor suppressor.
  • High p27Kip1 levels correlate with favorable prognosis in human cancers.
  • Decreased p27Kip1 is linked to increased tumor incidence in mouse models.

Purpose of the Study:

  • To investigate the largely unknown posttranscriptional mechanisms regulating p27Kip1 levels in cancer.
  • To determine which posttranscriptional regulatory pathways are essential for p27Kip1 turnover during tumor development.

Main Methods:

  • Utilized a series of allelic mouse models with specific p27Kip1 mutations.
  • Examined the impact of these mutations on different posttranscriptional regulatory pathways.
  • Assessed the necessity of these pathways for p27Kip1 turnover in the context of tumor development.

Related Experiment Videos

Main Results:

  • Identified specific posttranscriptional regulatory pathways influencing p27Kip1 stability.
  • Demonstrated that certain pathways are crucial for p27Kip1 turnover during tumorigenesis.
  • Observed surprising and unexpected results regarding the role of these pathways.

Conclusions:

  • p27Kip1 regulation in cancer primarily occurs posttranscriptionally, not via gene mutation or silencing.
  • The study highlights novel pathways involved in p27Kip1 degradation, offering new therapeutic targets.
  • Further research using these mouse models will elucidate the precise mechanisms of p27Kip1 regulation in cancer.